42 results about "Cells transplantation" patented technology

The present invention provides a human T cell lacking human leukocyte antigen (HLA) class I molecule and containing an exogenous ST6GALNAC6 gene, which has the following characteristics (a) and / or (b):(a) CD62L-positive and CD45RA-positive(b) a total ATP production rate of a human T cell-containing cell population of 400 pmol / min / 105 cells or more and a mitochondrial spare respiratory capacity of 40 pmol / min / 105 cells or more, 5-6 days after the application of T cell proliferation stimulation to the cell population. According to the present invention, a low-immunogenic human T cell that can remain stably in the body for a long period of time after transplantation is provided, and the development of a versatile CAR-T cell or TCR-T cell for allotransplantation becomes possible by using the human T cell.

The invention provides a bone marrow infusion pump for stem cell transplantation, and belongs to the technical field of stem cell infusion pumps. Comprising a machine body, a control panel is installed at the top of the machine body, a movable clamping frame is slidably connected into the machine body, a handle is installed on one side of the machine body, a base is installed at the bottom of the machine body, a piston push rod is installed at one end of the movable clamping frame, and a syringe is slidably connected to one end of the piston push rod; a connector is mounted at one end of the syringe, and a hose is mounted at one end of the connector. According to the infusion pump, by arranging the stress detection pipe clamp assembly and the adjustable clamping assembly, drawing type disassembly and assembly of a fault module of the infusion pump are achieved, the capacity of coping with emergencies is improved, it is guaranteed that stem cells in an injection cylinder are not affected by external force, the phenomenon of overflowing is avoided, a physical isolation barrier is formed, and the service life of the injection cylinder is prolonged. The leakage risk caused by collision or mistaken touch is effectively reduced, rapid clamping adaptation of the syringe can be achieved, and compatibility is improved.

The embodiment of the present invention discloses an induction culture medium, method and application for improving the viability and factor secretion ability of hair follicle-derived mesenchymal stem cells in a hypoxic environment. The induction culture medium includes a basal culture medium and an induction drug, and the induction drug includes transforming growth factor β, hepatocyte growth factor, cyclic adenosine monophosphate, triptolide, sodium hydrosulfide, lipopolysaccharide, hyaluronic acid, dexamethasone, L-glutamine and HEPES buffer. The induction culture medium provided by the present invention can promote the metabolism and energy production of hair follicle-derived mesenchymal stem cells, enhance the antioxidant capacity of cells, improve the survival rate and factor secretion ability of cells in a hypoxic environment, and solve the problems of low cell viability, slow growth, low cytokine secretion, etc. after transplanting cells into damaged tissue areas in the prior art.

Polycaprolactone (PCL) scaffolds having macropores interconnected with micorpores are provided. Tissue grafts that include the PCL scaffold having therapeutic cells encapsulated within the macropores are also provided. Also provided are methods of making the PCL scaffold and the tissue graft, and methods of transplanting cells into an individual using the tissue graft.

The invention belongs to the technical field of cell biology, and particularly relates to a cell culture method based on self-assembly microgel, a cell product and application. The cell culture method based on the self-assembled microgel comprises the following steps: culturing cells by adopting a cell culture medium, and adding the self-assembled microgel into a culture system. The cell culture method has the beneficial effects that the controllable and reversible self-assembly microgel scaffold is constructed by taking microgel with self-assembly capability as a basic construction unit, and three-dimensional wrapping, static culture and dynamic culture aiming at suspension cell types are realized in vitro; the cells obtained by the culture method can be transplanted in vivo, can be used for a clinical treatment scheme for assisting transplantation of cells in marrow cavities such as allogeneic hematopoietic stem cells and megakaryocytes, and can be used for optimizing cell therapy of hematological malignant tumors, thrombocytopenia and other hematological system malignant diseases.

The present invention deals with a cold-cleaning process for deriving a decellularized bone tissue sample or decellularized osteochondral tissue sample to be used as a medical device, or as a raw material.

Provided is a method for obtaining the germ cell lineage of an oviparous vertebrate more efficiently than conventional techniques. A host oviparous vertebrate is prepared at a developmental stage after the development of black pigmentary cells in the retina and before the formation of multiple layers of germ cells in the genitals, and isolated undifferentiated germ cells from a donor oviparous vertebrate are transplanted into the host oviparous vertebrate.

The application discloses a kind of for repairing cartilage decellularized cartilage matrix support and apoptotic corpuscle composition and its preparation method, composition includes: microporous support, support includes decellularized cartilage outer matrix and crosslinked organic polymer;Apoptotic corpuscle, apoptotic corpuscle exists in microporous support;Wherein, based on the volume 3.14mm 3 Microporous support, 0.01-0.02ug of apoptotic corpuscle is included.The combined support of the application can improve the activity of apoptotic corpuscle, prolong the action time of apoptotic corpuscle, achieve the effect of slow release, also can regulate joint cavity microenvironment, effectively promote joint cartilage repair, improve the repair effect of loss cartilage, avoid the security risks brought by traditional exogenous cell transplantation.

The present disclosure is generally directed to the use of biomaterial scaffolds engineered with SA-FasL for the transplantation of stem cell derived β-cells as a treatment for Type I diabetes. Early engraftment post-transplantation and subsequent maturation of these β-cells may be limited by the initial inflammatory response, which impacts the ability to sustain normoglycemia at long times. The survival and development of immature hPSC-derived β-cells transplanted on poly(lactide-co-glycolide) (PLG) microporous scaffolds into the peritoneal fat, a site being considered for clinical translation, was investigated. The scaffolds were modified with biotin for binding of a streptavidin-FasL (SAFasL) chimeric protein to modulate the local inflammatory microenvironment. The presence of FasL impacted infiltration of monocytes and neutrophils and altered their phenotypic response. Conditioned media generated from scaffolds explanted at day 4 did not impact hPSC-derived β-cell survival and maturation in vitro, which was not observed with unmodified scaffolds. Following transplantation, β-cell viability and differentiation were improved with SA-FasL modification. A sustained increase in insulin positive cell ratio was observed with SA-FasL modified relative to unmodified scaffolds. These results demonstrate that SA-FasL-modified scaffolds can mitigate initial inflammatory response and enhance β-cell engraftment and differentiation.

Sotorasib augments the KRAS-G12C mutant cancer cells response to TNFα by Increasing TNFR1 surface expression, which in turn upregulates TNFα and IFNy down-stream target genes and ultimately enhances cancer cell death. In TACE-dependent mechanism, Sotorasib inhibited TNFR1 shedding off the KRAS-G12C mutant cancer cells. Additionally, Sotorasib significantly promotes the expansion of tumor infiltrating lymphocytes (TILs). In, addition, it generates a “hot” tumor microenvironment with strikingly augmented T cell effector phenotype. These results suggest that sotorasib regulation of TNFa and IFNy plays a crucial role in generating a more immune active tumor microenvironment. Consistently, sotorasib combined with CAR-T adoptive cell transfer and anti-PD1 treatment enhanced their anti-tumor effect. Therefore, disclosed herein is a method for treating KRAS-G12C mutant cancer in a subject, the method involving adoptively transferring an effective amount of autologous or allogeneic immune effector cells (T cells) to the subject in combination with a KRAS-G12C inhibitor

This invention discloses a method for constructing a PBMC-derived humanized mouse scleroderma model. Human peripheral blood mononuclear cells are transplanted into immunodeficient mice, and a human immune system is reconstructed in the mice. Bleomycin is injected into the local skin of the mice in a round-point manner to induce fibrosis and form a scleroderma model. This application can more comprehensively simulate the complex pathological process of immune abnormalities and tissue fibrosis coexisting in human scleroderma, and provides a more realistic and systematic experimental platform for in-depth exploration of the immune mechanism of this disease.

The invention belongs to the technical field of biological medicines, and particularly relates to a pharmaceutical composition for treating thalassemia and application thereof. The invention provides a pharmaceutical composition for treating thalassemia, which comprises: (a) a cell population containing a first type of cells and a second type of cells, the cell population can be used for differentiating to generate red blood cells, target loci of the first type of cells are edited to increase red blood cells expressing functional hemoglobin generated by differentiation of the cell population, and target loci of the second type of cells are edited to generate target loci of the second type of cells; the target gene loci of the second type of cells are not edited; (b) a mobilizing agent. The medicine composition can achieve the effect of treating thalassemia through cell transplantation without removing marrow, and the clinical treatment risk of a patient is reduced.

The present invention provides in particular antibodies or antigen-binding fragments thereof which are specific for CD45. The antibodies include antibodies that are monospecific for CD45, as well as antibodies that are biparatopic for CD45. The antibodies are typically able to bind both human and cynomolgus monkey CD45. The antibodies of the invention have various uses involving targeting, depleting, and killing cells expressing CD45, particularly for the treatment of cancer or autoimmune diseases which are mediated by CD45 positive cells or prior to the transplant of cells.

The invention provides a leukemia cell strain induced by an AVEN-NUTM1 fusion gene as well as an establishment method and application of the leukemia cell strain. The leukemia cell strain can stably express the AVEN-NUTM1 fusion gene, can be subcultured in vitro for a long time and maintain the multiplication capacity, and can induce leukemia after being transplanted into a receptor animal. The establishment method comprises the following steps: infecting hematopoietic stem / progenitor cells by using a virus vector carrying an AVEN-NUTM1 fusion gene, transplanting the infected cells into a receptor mouse body to induce leukemia, separating leukemia cells from the diseased mouse body, and culturing in vitro to finally obtain the stable cell strain. The cell strain established by the invention fills the blank of lack of stable and reliable experimental models in the research field of NUTM1 related leukemia, and provides a key tool and platform for analyzing pathogenesis of the leukemia, screening therapeutic drugs and developing new therapeutic strategies.

The invention discloses a mouse gene knockout method and a constructed SP1 gene knockout mouse embryo model, and belongs to the technical field of biogenetics, the model construction method comprises the following steps: preparing a gene editing solution containing Cas9 and sgRNA for targeting a second exon region and a third exon region of a mouse SP1 gene by using a CRISPR / Cas9 gene editing technology; injecting the gene editing injection into a fertilized egg of a mouse; and transplanting two cells obtained by splitting the injected fertilized ova into the uterus of a pseudopregnant female mouse to obtain the SP1 gene knockout mouse embryo model. The SP1 gene in a mouse embryo is cut off by using a gene editing tool CRISPR / Cas9, the influence of the gene on embryo development is observed, the effect of the SP1 gene in embryo formation and abortion is researched, and a theoretical basis is provided for disease treatment.

The invention discloses a cell composition and application thereof in preparation of a preparation for treating diabetes mellitus. The cell composition contains pancreatic duct stem cells and functional islet cells formed by chemically inducing the pancreatic duct stem cells to differentiate. According to the invention, rat pancreatic duct stem cells derived from adult rats and functional islet cells chemically induced in vitro are transplanted through hepatic portal veins in a combined manner, so as to treat STZ modeling rat diabetes mellitus. Functional islet cells can directly and timely play a role in reducing blood sugar after entering the body; meanwhile, the transplanted pancreatic stem cells can be continuously amplified and gradually differentiated in vivo to form functional islet cells, so that the hypoglycemic effect is further continuously achieved, and diabetes can be treated for a longer time. The invention provides a method for treating diabetes mellitus through cell transplantation of human beings and other animals, and the method has important theoretical significance and huge social application value and economic value.

The invention discloses a fibroblast tumor cell related to skin-derived acute lymphocytic leukemia and application of the fibroblast tumor cell, and belongs to the technical field of biomedicine, and the cell is derived from a skin tissue microenvironment in a human leukemia cell transplantation nude mouse leukemia model. The cell name is mouse acute lymphocytic leukemia related fibroblast tumor cell HXLAF-HS, the preservation number is CCTCC NO: C2023341, the preservation date is December 7, 2023, and the preservation unit is China Center for Type Culture Collection. The HXLAF-HS cell provided by the invention can provide guidance for related pathogenesis of acute lymphocytic leukemia, new treatment schemes, preclinical evaluation of new drugs and the like, and has relatively high clinical application value.

Methods of treating bacterial infection in immunocompromised subjects and subjects with one or more underlying malignancies include administering a combination of meropenem and vaborbactam to the subject. Suitable subjects to be treated can include a subject with a history of ongoing leukemia or lymphoma, a subject that has had an organ transplant, stem cell transplant, bone marrow transplant, or splenectomy, a subject receiving immunosuppressive medications, a subject receiving bone marrow ablative chemotherapy, a subject with neutropenia and subject suffering from or having suffered from a malignancy.

The invention discloses application of salidroside in improvement of Alzheimer's disease by neural stem cell transplantation. The salidroside promotes NSC to be differentiated into cholinergic neurons, inhibits excessive proliferation of glial cells, regulates and controls the polarization state of microglial cells, and improves cell survival and memory functions after NSC transplantation. Salidroside regulates and controls SIRT3 expression in microglial cells, promotes NSC to be differentiated to cholinergic neurons, and inhibits differentiation of the microglial cells; meanwhile, by up-regulating SIRT3 expression, regulating and controlling the polarization state of the microglia, inhibiting activation of NLRP3 inflammasomes, promoting polarization of the microglia from M1 type to M2 type, and playing an anti-inflammatory role. By means of salidroside treatment, the cell survival rate and activity of APP / PS1 mice after NSC transplantation are remarkably improved, the cognitive function and anxiety behavior are improved, and the A beta deposition number and plaque area of the hippocampus area are reduced. The invention provides a new thought for preparing a new medicine for treating Alzheimer's disease.

The object of the present invention is to provide a decellularized graft which has any thickness and specific shape.The problem can be solved by a decellularized cellular structure of the present invention, which is a decellularized cultured cellular structure, characterized by having porosity ratio of 30% to 80%.

A nucleic acid encoding human frataxin protein, a gene therapy vector including the nucleic acid, and genetically modified cells containing the nucleic acid or the vector are disclosed. The encoded human frataxin protein includes upstream cell secretion and cell penetration peptides. The genetically modified cells may be used in a method of treating Friedreich's Ataxia by transplanting a cell genetically modified by a gene therapy vector including the nucleic acid encoding human frataxin protein into a patient.

The invention discloses a preparation method and application of a monoclonal cell with positive CAR (chimeric antigen receptor). The cell preparation method comprises the following steps: acquiring tumor cells and a lentiviral vector containing a target CAR gene, and transferring the tumor cells and the lentiviral vector to a 24-hole culture plate for mixed transfection culture; after culture is finished, centrifuging the culture solution, removing supernatant, and resuspending cell precipitate by using a culture medium; sorting the cell suspension, transplanting the sorted cells into a 96-well plate, and culturing for 7-14 days; and after the culture is finished, centrifuging the culture solution, removing the supernatant, and washing the cell precipitate with PBD to obtain the CAR-positive monoclonal cell. A series of cell strain lines capable of stably expressing the CAR gene are constructed through lentivirus transfection, a stable positive quality control product is provided for CAR-T cell detection, standardized and systematized operation of CAR-T detection is improved, it is ensured that a CAR-T detection result is accurate, credible and reliable, and it is ensured that CAR-T cells are safely and effectively used clinically.

Provided herein are methods of producing engineered target organs (e.g., a pancreas) and / or cells therefrom (e.g., islets) using a non-human mammal host. In some embodiments, the methods relate to injecting hypoimmunogenic human pluripotent stem cells (HIP-hPSC) into a blastocyst of a surrogate non-human mammal to produce a chimeric blastocyst and implanting the chimeric blastocyst into the uterus of the surrogate non-human mammal, wherein after implantation the chimeric blastocyst develops into a non-human mammal host comprising a target organ with chimeric contribution from the HIP-hPSCs. In further embodiments, the target organ and / or cells therefrom are transplanted into a human subject having a disease or condition. In some embodiments, the HIP-hPSCs comprise one or more modifications that reduce or eliminate expression of one or more MHC class I and / or MHC class II human leukocyte antigens and also increase expression of one or more tolerogenic factors.

The present application belongs to the technical field of animal model construction, and aims at the problem of the lack of human hepatic stellate cells leading to the liver fibrosis animal model, and provides a construction method and application of a liver fibrosis mouse model based on a human hepatic stellate cell strain.The present application uses an immunodeficient mouse as an animal model, uses luciferase and red fluorescent protein labeled LX-2, and injects MCT into the abdominal cavity to make a liver injury model of the mouse, injects LX-2 into the spleen after liver injury, transplants human LX-2 cells into the NSG mouse, and then injects CCl4 into the abdominal cavity of the mouse.Through the method, the implantation, distribution, proliferation and liver fibrosis of the transplanted LX-2 in the liver are successfully studied.The model is suitable for human in-vivo experiments of biological treatment and drug treatment and other treatment methods targeting hepatic stellate cells or fibroblasts.

This invention discloses a 3D scaffold for repairing defective lung injury, its construction method, and its applications, belonging to the field of biomedical materials and tissue engineering technology. This invention uses cationic polysaccharide chitosan and polymer γ-polyglutamic acid as raw materials, utilizing their electrostatic interaction to achieve cross-linking without cross-linking agents, and combines this with freeze-drying technology to prepare a three-dimensional spherical γ-PGA / CS composite scaffold. The above composite scaffold is combined with bone marrow stem cell exosomes (MSC-Exos) and type II alveolar epithelial cells (RLE-6TN). By loading exosomes onto the scaffold and implanting lung cells, local enrichment and targeted delivery are achieved, solving the problems of poor targeting of bone marrow stem cell exosomes and easy loss during transplantation of individual cells. This functional scaffold can accelerate lung function recovery by regulating the inflammatory microenvironment at the site of lung injury in SD rats, promoting lung cell regeneration, and reducing secondary lung tissue damage. It provides a novel implantable, minimally invasive treatment for defective lung injury-related diseases, possessing good clinical translational potential and application prospects in organ damage repair.

Polycaprolactone (PCL) scaffolds having macropores interconnected with micorpores are provided. Tissue grafts that include the PCL scaffold having therapeutic cells encapsulated within the macropores are also provided. Also provided are methods of making the PCL scaffold and the tissue graft, and methods of transplanting cells into an individual using the tissue graft.

The disclosure provides, in various embodiments, non-human animals that comprise a human immune cell engraftment and / or functional human immune system. The disclosure also provides, in various embodiments, methods of generating said non-human animals. The disclosure also provides, in various embodiments, methods of determining immunogenicity of antigens or an immunogenic fragment thereof or antigenic therapies and / or identifying agents that modulate immune response.

The present invention discloses the application of a proteolysis-targeting chimera, relating to the technical field of drug preparation. The key points of its technical solution are as follows: The present invention has developed a selective RNF4 degrader, RD6, which can effectively induce the degradation of RNF4 and apply it in liver cancer cell lines, including HEPG2, HCCLM6 and Huh7. In addition, the degrader RD6 exhibits significant anti-proliferation characteristics in liver cancer cell lines and shows promising in vivo efficacy in a mouse model transplanted with HCCLM6 cells. This provides a brand-new chemical tool and new insights for exploring liver cancer and its treatment methods.